Literature DB >> 1367500

Production of recombinant human erythropoietin in Bowes melanoma cells in suspension culture.

L Keay1, J M Walsh, R M Buchholz, J M Terando.   

Abstract

Recombinant DNA technology was used to insert a fetal liver genomic library ApaI fragment encoding for human erythropoietin (Epo) into Bowes melanoma cells. The cells expressed the erythropoietin gene, and Epo was secreted into the culture medium together with the normally-secreted tissue plasminogen activator. Attempts to grow the cells in glass spinners in Dulbecco's medium supplemented with fetal bovine serum produced cell aggregates growing in suspension. When calcium-free suspension culture media (Joklik, DME-S, McCoy 5A-S) were used, single cell suspension cultures were obtained and high Epo production observed. When attempts were made to scale up the small glass spinners, poor growth or Epo production occurred unless the vessels were aerated. This was shown to be because of the drop in pH, possibly due to CO2 accumulation, rather than due to oxygen depletion. It was shown that a semi-continuous operation could be achieved in aerated 8-1 spinners fitted with either a conventional stirrer or a vibromixer agitator. The system was scaled up to a 100-1 stainless steel vessel fitted with a vibromixer agitator. This system was operated for over 4 months with weekly harvests producing over 100 million units of Epo in about 1000-1 of culture fluid. Interference by the serum proteins with downstream purification of the hormone from the culture fluid made the use of serum-free media highly desirable. Studies showed that the Epo was produced in serum-free systems containing peptones.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1367500     DOI: 10.1007/bf00166780

Source DB:  PubMed          Journal:  Appl Microbiol Biotechnol        ISSN: 0175-7598            Impact factor:   4.813


  14 in total

1.  Bio-assay of erythropoietin in mice made polycythaemic by exposure to air at a reduced pressure.

Authors:  P M COTES; D R BANGHAM
Journal:  Nature       Date:  1961-09-09       Impact factor: 49.962

2.  Cloning and expression of the human erythropoietin gene.

Authors:  F K Lin; S Suggs; C H Lin; J K Browne; R Smalling; J C Egrie; K K Chen; G M Fox; F Martin; Z Stabinsky
Journal:  Proc Natl Acad Sci U S A       Date:  1985-11       Impact factor: 11.205

3.  Site-specific antibodies to human erythropoietin directed toward the NH2-terminal region.

Authors:  J M Sue; A J Sytkowski
Journal:  Proc Natl Acad Sci U S A       Date:  1983-06       Impact factor: 11.205

4.  The cultivation of animal cells and production of viruses in serum-free system.

Authors:  L Keay
Journal:  Methods Cell Biol       Date:  1978       Impact factor: 1.441

5.  The isolation of structural genes from libraries of eucaryotic DNA.

Authors:  T Maniatis; R C Hardison; E Lacy; J Lauer; C O'Connell; D Quon; G K Sim; A Efstratiadis
Journal:  Cell       Date:  1978-10       Impact factor: 41.582

6.  Isolation of human erythropoietin with monoclonal antibodies.

Authors:  S Yanagawa; K Hirade; H Ohnota; R Sasaki; H Chiba; M Ueda; M Goto
Journal:  J Biol Chem       Date:  1984-03-10       Impact factor: 5.157

7.  Large-scale mammalian cell culture: Design and use of an economical batch suspension system.

Authors:  W R Tolbert; R A Schoenfeld; C Lewis; J Feder
Journal:  Biotechnol Bioeng       Date:  1982-07       Impact factor: 4.530

8.  Human erythropoietin gene: high level expression in stably transfected mammalian cells and chromosome localization.

Authors:  J S Powell; K L Berkner; R V Lebo; J W Adamson
Journal:  Proc Natl Acad Sci U S A       Date:  1986-09       Impact factor: 11.205

9.  Purification of human erythropoietin to homogeneity by a rapid five-step procedure.

Authors:  G Krystal; H R Pankratz; N M Farber; J E Smart
Journal:  Blood       Date:  1986-01       Impact factor: 22.113

10.  Properties of plasminogen activators formed by neoplastic human cell cultures.

Authors:  D B Rifkin; J N Loeb; G Moore; E Reich
Journal:  J Exp Med       Date:  1974-05-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.